Drug Res (Stuttg) 2021; 71(03): 138-148
DOI: 10.1055/a-1288-4078

Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment

Saptarshi Chatterjee
1  Assistant Professor, Department of Microbiology, Adamas University, Kolkata
› Institutsangaben


Remdesivir is presently been considered as ‘molecule of hope’ to curb the menace of COVID19. Non-availability of any USFDA approved drug has led to several attempt of drug-repurposing and development of new therapeutic molecules. However, Remdesivir has been found to be effective against a broad range of virus including SARS, MERS and COVID 19 through in-vitro studies. Several clinical research attempt are presently being conducted showing promising result yet not conclusive. This review summarized all such clinical trials to critically appraise the usage of Remdesivir against COVID 19 along with the publications related to the results of the clinical studies. The present regulatory aspect i. e. Emergency Use Authorization (EYA) and information of molecule and plausible mechanism is also dealt.


Eingereicht: 29. Mai 2020

Angenommen: 06. Oktober 2020

29. Oktober 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany